GPRC5D Biological Pathways Reviews

Videos

Videos

Bispecific Antibodies, CAR T-Cell Therapy, and BCMA-Directed Therapy for the Treatment of Multiple Myeloma With Curative Intent

02/23/2023

Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.

Sundar Jagannath, MD, provides...

02/23/2023

Oncology

Dan Vogl, MD, University of Pennsylvania

Videos

Bispecific T-Cell Engagers and Novel Approaches for the Treatment of Multiple Myeloma

02/23/2023

Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.

Dan Vogl, MD discusses options...

02/23/2023

Oncology

Videos

What Is the Optimal Combination for Patients With Multiple Myeloma in Early Relapse?

02/16/2023

Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Faith E. Davies, MD, provides an...

02/16/2023

Oncology

Conference Coverage

The “ABCs” of Immunotherapy for Patients With Acute Myeloid Leukemia

09/06/2024

At the 2024 SOHO meeting, Marion Subklewe, MD, discusses the current landscape and future development of immune and cellular therapies for patients with acute myeloid leukemia.

At the 2024 SOHO meeting, Marion...

09/06/2024

Oncology

Conference Coverage

Challenges of Treating Secondary Acute Myeloid Leukemia With Standard Therapies

09/05/2024

Pinkal Desai, MD discusses the challenges of existing treatment options for patients with secondary acute myeloid leukemia and the need for further development of therapies for this disease subset.

Pinkal Desai, MD discusses the...

09/05/2024

Oncology

Alessandro Santin, MD, Yale Cancer Center

Videos

Efficacy and Safety of Sacituzumab Govetican for Patients With Advanced Endometrial Cancer

09/05/2024

Alessandro Santin, MD, shares insights from the endometrial cancer cohort of the TROPiCS-03 trial, which evaluated sacituzumab govetican among patients with advanced endometrial cancer who have been heavily pretreated.

Alessandro Santin, MD, shares...

09/05/2024

Oncology

Conference Coverage

Developments in Utilizing Interferons for the Treatment of Myeloproliferative Neoplasms

09/04/2024

Abdulraheem Yacoub, MD, shares expert insight into the use of interferons for the treatment of patients with myelofibrosis, essential thrombocythemia, and polycythemia vera.

Abdulraheem Yacoub, MD, shares...

09/04/2024

Oncology

Conference Coverage

Exploring Developments and Challenges of Immunological Approaches in AML Treatment

09/04/2024

At the 2024 Society of Hematologic Oncology meeting, Eduardo Rego, MD, shares his interest in reviewing data on novel research in acute myeloid leukemia treatment development, specifically the incorporation of immunological approaches.

At the 2024 Society of...

09/04/2024

Oncology

Conference Coverage

Analyzing Data on the Improvement of International Outcomes of Acute Myeloid Leukemia Therapy

09/04/2024

Eduardo Rego, MD, shares expert insight into International Consortium on Acute Leukemia research on improving the outcomes of therapy for patients with AML treated in Latin America compared to the outcomes of those treated in the US and...

Eduardo Rego, MD, shares expert...

09/04/2024

Oncology

Videos

Potential for Measurable Residual Disease as an End Point in Chronic Lymphocytic Leukemia Research

09/03/2024

Talal Hilal, MD, discusses an analysis on whether measurable residual disease can serve as a valuable end point in chronic lymphocytic leukemia clinical trials.

Talal Hilal, MD, discusses an...

09/03/2024

Oncology

Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute

Videos

Inavolisib Plus Palbociclib and Fulvestrant for Patients With Relapsed PIK3CA-Mutated Advanced Breast Cancer

09/03/2024

Demetria J. Smith-Graziani , MD, MPH;

Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast...

Demetria Smith-Graziani, MD,...

09/03/2024

Oncology

Videos

Best Management Practices for a Patient With Pediatric Low-Grade Glioma

09/02/2024

Lindsey Hoffman, DO, discusses the course of treatment she would take for a patient with BRAF V600E-mutated pediatric ganglioglioma.

Lindsey Hoffman, DO, discusses...

09/02/2024

Oncology

Videos

Exciting Developments in Chronic Lymphocytic Leukemia Treatment Research

08/28/2024

Matthew Davids, MD, discusses groundbreaking developments in the chronic lymphocytic leukemia treatment landscape, focusing on the latest data from the ongoing AMPLIFY and MAJIC studies.

Matthew Davids, MD, discusses...

08/28/2024

Oncology

GPRC5D

ALIASES

G-protein coupled receptor family C group 5 member D

References

G protein-coupled receptor class C group 5 member D (GPRC5D) is a gene expressed in the hair follicle and malignant bone marrow plasma cells.¹ G protein-coupled receptor proteins are cell surface receptors located in the plasma membrane. Activation of the protein occurs when it binds to an external signaling molecule, which causes a conformational change and triggers an interaction between the protein and an available G protein.²

Understanding the Role of GPRC5D

Expression Percentages per Cancer Type

Multiple Myeloma

88%

Resources

News

GPRC5D-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

03/23/2023

Amber Denham

Phase 1 results from the POLARIS trial demonstrate that GPRC5D-targeted CAR-T cell therapy (OriCAR-017) is a promising treatment modality for patients with relapsed/refractory multiple myeloma.

Phase 1 results from the POLARIS...

03/23/2023

Oncology

News

Promising Clinical Efficacy for GPRC5D-Targeting CAR-T Cell Therapy in R/R Multiple Myeloma

03/23/2023

Amber Denham

GPRC5D-targeting CAR-T cell therapy demonstrated a promising clinical efficacy and manageable safety profile in patients with relapsed/refractory multiple myeloma.

GPRC5D-targeting CAR-T cell...

03/23/2023

Oncology

News

Talquetamab Shows Promise as Novel Agent for Patients With Multiple Myeloma

06/20/2022

Yvette C. Terrie, BSPharm, RPh

Yvette C. Terrie, BSPharm, RPh ...

Study findings show the novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, demonstrates substantial activity against MM cell lines and primary MM cells.

Study findings show the novel...

06/20/2022

Oncology

News

Pirtobrutinib Demonstrates Promising Efficacy, Safety Among Patients With B-Cell Malignancies With Richter Transformation

09/06/2024

Amber Denham ;

Pirtobrutinib treatment shows encouraging safety and activity among patients with relapsed/refractory B-cell malignancies who experience Richter transformation, according to a subgroup analysis from the phase 1/2 BRUIN study.

Pirtobrutinib treatment shows...

09/06/2024

Oncology

Conference Coverage

Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer

09/05/2024

Allison Casey ;

According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...

According to updated results...

09/05/2024

Oncology

News

Optimal Trastuzumab Deruxtecan Dose for Patients With HER2-Positive Advanced Colorectal Cancer

09/05/2024

Stephanie Holland ;

According to results from the phase 2 DESTINY-CRC02 trial, 5.4 mg/kg of trastuzumab deruxtecan is preferable to 6.4 mg/kg among patients with HER2-positive metastatic colorectal cancer.

According to results from the...

09/05/2024

Oncology

News

Tarlatamab Sustained Clinical Benefit Among Previously Treated Patients With Small Cell Lung Cancer

09/04/2024

Stephanie Holland ;

According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.

According to extended follow-up...

09/04/2024

Oncology

News

Autologous Hematopoietic Cell Transplantation Demonstrates Improved Outcomes Over CAR-T Among Patients With Relapsed LBCL Who Achieve Complete Remission

08/30/2024

Amber Denham ;

According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...

According to results from a...

08/30/2024

Oncology

News

Belzutifan Improved Survival, Response Among Patients With Advanced Clear-Cell Renal Cell Carcinoma

08/30/2024

Stephanie Holland ;

According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...

According to results from the...

08/30/2024

Oncology

News

Revumenib Demonstrates Clinical Benefit Among Patients With High-Risk, R/R KMT2Ar Acute Leukemia

08/30/2024

Amber Denham ;

According to phase 1/2 results from the AUGMENT study, revumenib, an inhibitor of the menin-lysine methyltransferase 2A interaction, demonstrated high remission rates with a predictable safety profile among patients with relapsed/refractory...

According to phase 1/2 results...

08/30/2024

Oncology

News

Sovleplenib Demonstrates Clinically Meaningful Response Among Patients With Chronic Primary Immune Thrombocytopenia

08/29/2024

Amber Denham ;

Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.

Sovleplenib, a novel spleen...

08/29/2024

Oncology

News

Lymph Node Dissection Improved Overall Survival Among Patients With Stage 3 Endometrial Cancer

08/29/2024

Stephanie Holland ;

According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.

According to results from a...

08/29/2024

Oncology

News

Hearing Loss Among Pediatric Patients with Neurofibromatosis Type 1

08/29/2024

Allison Casey ;

According to a review of audiometric data, the rate of hearing loss among patients with neurofibromatosis type 1 (NF1) compared to the general population was higher than expected.

According to a review of...

08/29/2024

Oncology

Podcasts

Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center

Podcasts

Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial

03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...

Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.

Petros Grivas, MD, PhD, shares...

03/07/2024

Oncology

Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA

Podcasts

Neoadjuvant Chemotherapy Plus HER2-Targeted Therapy for Early Stage HER2-Positive Breast Cancer

02/16/2023

Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.

Sara Hurvitz, MD, shares how she...

02/16/2023

Oncology

Michael Hall, MD, Fox Chase Cancer Center

Podcasts

Advances in Genetic Testing for Patients With Gastrointestinal Cancers

12/20/2022

Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.

Michael Hall, MD, reviews his...

12/20/2022

Oncology

Podcasts

Enfortumab Vedotin for Metastatic Urothelial Cancer After Progression on Platinum-Based Chemotherapy

11/15/2022

Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.

Petros Grivas, MD, PhD, shares...

11/15/2022

Oncology

Podcasts

BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma

07/29/2022

Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.

Margherita Rimini, MD, discusses...

07/29/2022

Oncology

Ruth He, MD, Lombardi Comprehensive Cancer Center

Podcasts

Durvalumab Plus Chemotherapy Improves Outcomes in Biliary Tract Cancer Across Primary Tumor Locations

07/22/2022

Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...

Ruth He, MD, discusses findings...

07/22/2022

Oncology

Arndt Vogel, MD, Hannover Medical School

Podcasts

Pemigatinib for Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

07/14/2022

Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

Arndt Vogel, MD, shares results...

07/14/2022

Oncology

Petros Grivas, MD, Fred Hutchinson Cancer Center

Podcasts

Sacituzumab Govitecan Plus Pembrolizumab Yields Encouraging Response Rates in Metastatic Urothelial Cancer

06/22/2022

Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Petros Grivas, MD, shares...

06/22/2022

Oncology

Podcasts

Maintenance Therapy With Cabozantinib Shows No Significant Benefit vs Placebo for Metastatic Urothelial Carcinoma

06/21/2022

Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.

Robert Jones, MD, shares results...

06/21/2022

Oncology

Podcasts

Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer

06/20/2022

In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.

In part 2 of this 2-part podcast...

06/20/2022

Oncology

Interactive

Quiz

Quiz: Where is the GPRC5D Gene Expressed?

03/23/2023

True or False: The GPRC5D gene is typically expressed in hair follicles, but CD138-positive multiple myeloma cells have also been found to express GPRC5D.

True or False: The GPRC5D gene...

03/23/2023

Oncology

Quiz

Quiz: Principles Behind Choosing Optimal Therapeutic Agent Combinations for Patients With MM

03/20/2023

According to Dr Faith E. Davies, MD, which of the following is NOT a principle behind selecting an optimal combination of therapeutic agents for patients with multiple myeloma in the early relapse stage?

According to Dr Faith E. Davies,...

03/20/2023

Oncology

Quiz

Efficacy of Revumenib Among Patients With Acute Leukemia

09/06/2024

True or False: According to results from the AUGMENT trial, revumenib demonstrated high remission rates with a predictable safety profile among patients with relapsed/refractory KMT2Ar acute leukemia.TrueFalse

True or False: According to...

09/06/2024

Oncology

Quiz

Well-Being and Quality of Life in Endometrial Cancer

08/28/2024

Do you know which factors can have the greatest impact on psychological well-being and overall quality of life among patients who have undergone surgery for endometrial cancer? Find out with our quiz.

Do you know which factors can...

08/28/2024

Oncology

Quiz

Sacituzumab Govitecan for Patients With Heavily Pretreated Advanced or Metastatic Endometrial Cancer

08/28/2024

Do you know whether sacituzumab govitecan showed promising efficacy among patients with heavily pretreated advanced or metastatic endometrial cancer? Test your knowledge with our quiz.

Do you know whether sacituzumab...

08/28/2024

Oncology

Quiz

Efficacy of Zilurgisertib Alone or Combined With Ruxolitinib in Myelofibrosis

08/22/2024

True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...

True or False: According to...

08/22/2024

Oncology

Quiz

Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer

08/08/2024

Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?

Do you know whether maintenance...

08/08/2024

Oncology

Quiz

08/08/2024

Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...

Based on results from the phase...

08/08/2024

Oncology

Quiz

Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer

08/05/2024

True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...

True or False: According to...

08/05/2024

Oncology

Quiz

Improving Long-Term Outcomes for Patients With HER2-Positive Early-Stage Invasive Breast Cancer

07/15/2024

According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?

According to the final analysis...

07/15/2024

Oncology

Quiz

Ibrutinib Plus Venetoclax For Patients With TP53-Mutated Mantle Cell Lymphoma

07/12/2024

Oncology

Quiz

Weekly Combination Therapy for Patients With R/R Multiple Myeloma

07/11/2024

Oncology

GPRC5D Targeting Anticancer Drugs

GPRC5D is a promising immunotherapeutic target, particularly in patients with multiple myeloma. This table outlines therapies targeting GPRC5D in the pipeline.

View Table

GPRC5D Targeting Anticancer Drugs in the Pipeline
Generic Drug Name	Potential Indications
Talquetamab¹	A first-in-class investigational bispecific antibody targeting both GPRC5D and CD3 being evaluated for the treatment of patients with relapsed or refractory multiple myeloma.

GPRC5D Biological Pathways Reviews

Videos

GPRC5D

Understanding the Role of GPRC5D

Expression Percentages per Cancer Type

Resources

Podcasts

Interactive

GPRC5D Targeting Anticancer Drugs

Specialties

Events

Year Round Education

HMP Global Products